GAG. Annerén

G. Annerén

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


G. Annerén has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sickness absence in Swedish parents of children with Down’s syndrome: relation to self‐perceived health, stress and sense of coherence

    by G. Hedov, K. Wikblad, G. Annerén

    The aims of present study were to study sickness absence among Swedish parents of children with Down's syndrome (DS) and to compare their rates of absence with those of control parents. Sickness absence data for 165 DS parents were compared with those for 174 control parents; all data were for the period 1997-2000. Sickness absence rates were also related to parental self-perceived health, stress and sense of coherence. The self-administrated measures of parental self-perceived health, stress and sense of coherence were compared with the number of days of sickness absence. In about two-thirds of the parents in both the study and the control group, no days of sickness absence were registered. Six of the DS parents had remarkably large numbers of days of sickness absence (more than 100 per year). None of the control parents had such high sickness absence rates. It is speculated that there is a small group (less than 5%) of parents who are more vulnerable to the birth of a child with DS. Apart from these six DS parents, sickness absence was not more frequent among the DS parents than among the control parents. DS parents stayed at home to care for their sick DS child three times more often than control parents did for their non-disabled child. DS fathers took greater responsibility in the care of their temporarily sick child and stayed at home to care for the child even more often than control mothers did. DS parents with sickness periods experienced small deterioration in self-perceived health, significantly higher stress and decreased sense of coherence in comparison with parents without sickness periods. There was a great similarity in sick leave rates due to one's own sickness between DS and control parents, but a small group of DS parents (<5%) may be more vulnerable. DS fathers stayed at home to care for their sick DS child remarkably often.


  • First information and support provided to parents of children with Down syndrome in Sweden: clinical goals and parental experiences

    by G Hedov, K Wikblad, G Annerén

    When parents are informed that their newborn child has Down syndrome (DS), they often respond with a traumatic crisis reaction. The aims of this study were to assess the clinical goals regarding the first information and support provided to parents of newborn children with DS at the Swedish paediatric departments, and to analyse the parents' experiences of how they were first informed and treated. Data were collected during 1992–1993 from all of the 51 departments of paediatrics in Sweden. Information on the parents' experiences, collected retrospectively in 1996, was based on recollection by 165 parents of 86 children with DS born between 1989 and 1993 at 10 of the paediatric departments considered representative for Sweden. Seventy‐five percent of the families were informed about the diagnosis within 24 h post partum. Some parents felt they were informed too late, and a few parents that they were told too soon. Half of the parents were satisfied with the timing. About 70% of the parents considered the information insufficient and 60% felt that they had been unsupported. Seventy percent would have liked more frequent information. Parental criticisms concerning the way in which the information was provided were that they received too much negative information about DS and that both the communication skills and the basic knowledge of DS on the part of the professionals could have been better. Conclusion: The Swedish paediatric departments fall short of their reported strong clinical goals regarding the initial information in Sweden, and improvements in this area are desirable.


  • Utilization of medical care among children with Down’s syndrome

    by C. Frid, G. Annerén, F. Rasmussen, C. Sundelin, P. Drott

    Background The present authors have previously found an increased mortality rate in children with Down’s syndrome (DS) and a congenital heart defect (CHD). The aim of the present study was to investigate the utilization of medical care in relation to congenital malformations in DS.Method Retrospectively, 211 children with DS born between 1973 and 1980 in the northern part of Sweden were followed up for at least 17 years (1973–1997). The duration of neonatal care was compared with that of children with DS born between 1995 and 1998 in the same region.Results Neonatal care was reduced over time. Almost 50% of the children had CHD, and before 10 years of age, these subjects were admitted for inpatient care twice as often as children with DS who did not have malformations, and had more than 12 times as many inpatient days per month. The existence of a gastrointestinal or other malformation increased inpatient days per month four and two times, respectively, compared to healthy children with DS. During the first 10 years of life, children with DS and a CHD accounted for 71% of all inpatient days caused by infections. No gender differences were observed.Conclusions At a group level, the presence of a CHD was the most important congenital abnormality in determining utilization of medical care and the burden of infections in the population of children with DS.


  • Mortality in Down’s syndrome in relation to congenital malformations

    by C. Frid, P. Drott, B. Lundell, F. Rasmussen, G. Annerén

    Down’s syndrome (DS) is the most common form of intellectual disability. The syndrome is characterized by congenital malformations, especially of the heart and gastrointestinal tract, which can result in high mortality rates in the affected population. Many improvements have been made in the medical treatment of this syndrome during the past few decades and the survival of individuals with DS has increased in the industrial world. The aim of the present study was to investigate mortality in relation to congenital malformations. Medical records from all liveborn children with DS delivered between 1973 and 1980 in northern Sweden were studied, and malformations and causes of death were recorded. Out of the 219 children included in the study, a congenital heart defect was reported in 47.5% of subjects, 42.1% of whom had complete atrioventricular septal defect. Gastrointestinal tract malformations were present in 7.3% of subjects, and was frequently associated with a cardiac malformation and a very high mortality rate. Other major and minor congenital anomalies were present in 5.5% and 5.5% of subjects, respectively. In the 14.5‐year follow‐up of 213 children, the rate of survival was 75.6%. Mortality rates within one and 10 years after birth were 14.6% and 23.5%, respectively. Mortality within 10 years differed significantly between children with (44.1%) and without (4.5%) a congenital heart defect. A very high mortality rate was observed among children with a congenital heart defect, especially when it was combined with a gastrointestinal malformation.


  • Open Access

    Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development

    by G Anneren, T Tuvemo, C Carlsson-Skwirut, T Lonnerholm, P Bang, V R Sara, J Gustafsson

    BACKGROUND Learning disability and short stature are cardinal signs of Down’s syndrome. Insulin-like growth factor I (IGF-I), regulated by growth hormone (GH) from about 6 months of age, may be involved in brain development. AIMS To study long term effects of GH on linear growth and psychomotor development in young children with Down’s syndrome. Study design—Fifteen children with Down’s syndrome were treated with GH for three years from the age of 6 to 9 months (mean, 7.4). Linear growth, psychomotor development, skeletal maturation, serum concentrations of IGF-I and its binding proteins (BPs), and cerebrospinal fluid (CSF) concentrations of IGF-II were studied. RESULTS The mean height of the study group increased from −1.8 to −0.8 SDS (Swedish standard) during treatment, whereas that of a Down’s syndrome control group fell from −1.7 to −2.2 SDS. Growth velocity declined after treatment stopped. Head growth did not accelerate during treatment. No significant difference in mental or gross motor development was found. The low concentrations of serum IGF-I and IGFBP-3 became normal during GH treatment. CONCLUSIONS GH treatment results in normal growth velocity in Down’s syndrome but does not affect head circumference or mental or gross motor development. Growth velocity declines after treatment stops.


    • 1 January 1998
      • Vol. 9  (4) , 265-70

    Linkage analysis excludes familial congenital hypothyroidism from chromosome 21.

    by B E Ahlbom, M Yaqoob, G Annerén, A Larsson, A Ilicki, C Wadelius

    Congenital hypothyroidism (CH) is a heterogeneous disorder with largely unknown causes, affecting 1/3000-1/4000 new-borns. Individuals with Down syndrome have a much higher incidence of CH than the normal population, probably due to the extra copy of chromosome 21. Moreover, a girl has recently been described with CH and an interstitial deletion of proximal 21q, possibly revealing a recessive disease allele on the undeleted chromosome. To establish whether chromosome 21 is also involved in the etiology of familial cases of presumably autosomal recessive CH, we investigated 22 families with recessive CH, using 10 microsatellite markers from 21q. Linkage analysis allowing for heterogeneity revealed no signs of linkage even in a small proportion of the families, and two-point analysis of the markers made it possible to exclude the long arm of chromosome 21 from containing any major disease-causing gene.

    • 20 September 1995
      • Vol. 92  (38) , 3425-30

    [Skeletal dysplasia. Medical interdisciplinary care is necessary for optimal treatment].

    by K H Gustavson, G Annerén, O Axelsson, L Eriksson, J Gustafsson, T Lönnerholm, L Rehnberg

    • 29 September 1993
      • Vol. 90  (39) , 3319-20

    [Children with Down syndrome. How are new parents supported?].

    by G Hedov, G Annerén

  • GROWTH HORMONE THERAPY OF CHILDREN WITH DOWN SYNDROME RESULTS IN NORMALIZED GROWTH VELOCITY

    by J Gustafsson, C Carlsson-Skwirut, V R Sara, T Tuvemo, G Annerén